Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui

DRUG4 trials

Sponsors

Gilead Sciences Inc., Aalborg University Hospital, Institut Regional Du Cancer De Montpellier, Associazione Italiana Per Lo Studio Del Pancreas

Conditions

Locally Advanced/Metastatic Urothelial CancerPancreatic cancerlocal advenced pancreatic adenocarcinomapancreatic ductal adenocarcinoma

Phase 2

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

RecruitingCTIS2023-508302-24-00

Gilead Sciences Inc.Locally Advanced/Metastatic Urothelial Cancer

Start: 2019-05-07Target: 116Updated: 2025-10-22

PHASE II study evaluating the benefit of Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

RecruitingCTIS2024-515344-23-00

Institut Regional Du Cancer De Montpellierlocal advenced pancreatic adenocarcinoma

Start: 2021-06-17Target: 103Updated: 2025-03-24

A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer

RecruitingCTIS2024-514291-41-00

Aalborg University HospitalPancreatic cancer

Start: 2023-10-20Target: 96Updated: 2025-02-04

Phase 3

A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)

Not yet recruitingCTIS2024-519031-42-00

Associazione Italiana Per Lo Studio Del Pancreaspancreatic ductal adenocarcinoma

Target: 261Updated: 2024-11-18

Related Papers

Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.

2025-11-20